StemCell Therapy

Fulgent Genetics Inc (NASDAQ:FLGT) has been assigned a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating.

Brokers have set a 1 year consensus price objective of $4.35 for the company and are anticipating that the company will post ($0.05) EPS for the current quarter, according to Zacks. Zacks has also given Fulgent Genetics an industry rank of 70 out of 255 based on the ratings given to related companies.

Several equities analysts have recently weighed in on FLGT shares. Credit Suisse Group decreased their price target on shares of Fulgent Genetics from $6.50 to $6.00 and set an outperform rating on the stock in a research note on Thursday, March 1st. Piper Jaffray Companies downgraded shares of Fulgent Genetics from an overweight rating to a neutral rating in a research note on Thursday, March 1st. Finally, ValuEngine raised shares of Fulgent Genetics from a sell rating to a hold rating in a research note on Wednesday, May 2nd.

Shares of Fulgent Genetics traded down $0.27, hitting $4.19, during midday trading on Friday, MarketBeat.com reports. The companys stock had a trading volume of 11,472 shares, compared to its average volume of 12,262. The company has a market cap of $79.79 million, a P/E ratio of -38.09 and a beta of 0.28. Fulgent Genetics has a 12-month low of $2.72 and a 12-month high of $7.04.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Monday, May 7th. The company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.04) by ($0.02). The business had revenue of $4.65 million during the quarter. Fulgent Genetics had a negative return on equity of 7.62% and a negative net margin of 26.57%. analysts expect that Fulgent Genetics will post -0.29 earnings per share for the current year.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes.

Get a free copy of the Zacks research report on Fulgent Genetics (FLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Continued here:
Analysts Set $4.35 Price Target for Fulgent Genetics Inc ...

This entry was posted on June 26, 2018 at 8:45 am and is filed under Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |